Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.50 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1913725 | 0.86 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL13679358 | 0.86 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL29021042 | 0.86 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1913913 | 0.86 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL3830765 | 0.86 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL8348935 | 0.86 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1913736 | 0.86 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1914043 | 0.86 | CACNA2D1 (0.47) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL5960145 | 0.84 | SMN1; SMN2 (0.48) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL1913657 | 0.81 | CACNA2D1 (0.42) | CACNA2D1CACNB3CACNA1CPGRADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10125104-B2 | Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof | Asta Pharmaceuticals Co., Ltd. (JP) | 2018-11-13 | — | — | US | disclosed |
| US-20170226159-A1 | METHOD FOR PRODUCING HYDROPHOBIC PEPTIDE | KANEKA CORPORATION (JP) | 2017-08-10 | — | — | US | disclosed |
| EP-3199540-A1 | METHOD FOR PRODUCING HYDROPHOBIC PEPTIDE | Kaneka Corporation (JP) | 2017-08-02 | — | — | EP | disclosed |
| CN-107001409-A | Method for producing hydrophobic peptide | 株式会社钟化 | 2017-08-01 | — | — | CN | disclosed |
| EP-3147279-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | Fuji Chemical Industry Co., Ltd. (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20170081289-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | FUJI CHEMICAL INDUSTRIES CO., LTD. (JP) | 2017-03-23 | — | — | US | disclosed |
| US-9302980-B2 | Process for producing solid amino acid | KANEKA CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| EP-2810933-A1 | METHOD FOR PRODUCING SOLID AMINO ACID | Kaneka Corporation (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-20140343289-A1 | PROCESS FOR PRODUCING SOLID AMINO ACID | KANEKA CORPORATION (JP) | 2014-11-20 | — | — | US | disclosed |
| CN-104093699-A | Method for producing solid amino acid | KANEKA CORP | 2014-10-08 | — | — | CN | disclosed |
| WO-2007101252-A2 | TARGETED DELIVERY OF PHARMACEUTICAL COMPOUNDS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-1499583-A1 | PROCESS FOR PREPARING HIGHLY FUNCTIONALIZED Y-BUTYROLACTAMS AND Y-AMINO ACIDS | Warner-Lambert Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20030236415-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | BLAZECKA PETER G (CA) | 2003-12-25 | — | — | US | disclosed |
| US-20030225149-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | BLAZECKA PETER G (CA) | 2003-12-04 | — | — | US | disclosed |
| WO-2003093220-A1 | PROCESS FOR PREPARING HIGHLY FUNCTIONALIZED Y-BUTYROLACTAMS AND Y-AMINO ACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081289-A1 | CAROTENOID DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, OR PHARMACEUTICALLY ACCEPTABLE ESTER OR AMIDE THEREOF | NR2E3, NR3C2, NR5A1 | CACNA2D1 4592/4885CACNB3 2088/4885CACNA1C 3219/4885 |
| US-10125104-B2 | Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof | NR2E3, NR3C2, NR5A1 | CACNA2D1 4592/4885CACNB3 2088/4885CACNA1C 3219/4885 |
| US-20030236415-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | GABRB2, GABRG2, GABRB1 | CACNA2D1 419/4885CACNB3 431/4885CACNA1C 202/4885 |
| US-20030225149-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | GABRB2, GABRG2, GABRB1 | CACNA2D1 419/4885CACNB3 431/4885CACNA1C 202/4885 |
| US-20170226159-A1 | METHOD FOR PRODUCING HYDROPHOBIC PEPTIDE | VIP, HM13, HDGF | CACNA2D1 3957/4885CACNB3 2884/4885CACNA1C 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.